FDA Approves Rytelo (telomerase inhibitor oligonucleotide) for transfusion-dependent anemia in low- to intermediate-1 risk MDS
The FDA has approved Rytelo, an oligonucleotide telomerase inhibitor, for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) accompanied by transfusion-dependent anemia. This indication specifically targets individuals who require 4 or more red blood cell units over an 8-week period and have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESA). The approval addresses a clinical need in a subset of MDS patients where ESA therapy is ineffective or not an option, offering a new therapeutic avenue for managing transfusion burden. Rytelo is administered as an intravenous infusion every 4 weeks, with recommendations for premedication to mitigate infusion-related reactions and specific guidelines for dose modifications based on adverse events. Clinicians should note that treatment should be discontinued if there is no reduction in red blood cell transfusion burden after 24 weeks (6 doses) or if unacceptable toxicity occurs.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Not reported in label.
Rytelo is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
The recommended dosage of Rytelo is 7.1 mg/kg administered as an intravenous infusion over 2 hours every 4 weeks. Premedicate prior to dosing with diphenhydramine (or equivalent) 25 mg to 50 mg and hydrocortisone (or equivalent) 100 mg to 200 mg, administered at least 30 minutes prior to dosing to prevent or reduce potential infusion-related reactions. Monitor patients for adverse reactions for at least one hour after infusion. Discontinue Rytelo if a patient does not experience a decrease in red blood cell transfusion burden after 24 weeks of treatment (administration of 6 doses) or if unacceptable toxicity occurs. Dose reductions for Grade 3 and Grade 4 adverse reactions: first reduction to 5.6 mg/kg, second reduction to 4.4 mg/kg. Permanently discontinue if the patient cannot tolerate 4.4 mg/kg. For hematologic adverse reactions (thrombocytopenia, neutropenia), delay treatment until recovery (platelets ≥50 × 10^9/L, ANC ≥1 × 10^9/L) and modify dose per tables; discontinue after specified occurrences. For non-hematologic adverse reactions (e.g., infusion-related reactions, elevated LFTs), interrupt infusion or delay treatment until recovery to Grade 1 or baseline, with dose reductions or discontinuation per tables. Monitor complete blood cell counts prior to administration, weekly for first two cycles, prior to each cycle thereafter, and as clinically indicated. Monitor liver function tests prior to administration, weekly for first cycle, prior to each cycle thereafter, and as clinically indicated.
trial data not available in label
Not reported in label.
Not reported in label.
View Original Abstract ↓
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients.
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
From Other Specialties
